Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.53 |
| ▸ | FPR2 | P25090 | 2/20 | 0.53 |
| ▸ | GRN | P28799 | 2/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307460 | 1.00 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4814309 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4572568 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4186349 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL9830454 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL6307464 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL15857620 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7331518 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4186354 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL16850468 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | ALDH1A1 410/4885MEN1 3047/4885LMNA 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.